Tweet
Front Pharmacol
. 2020 Oct 9;11:572009.
doi: 10.3389/fphar.2020.572009. eCollection 2020.
Targeting Neutrophils to Treat Acute Respiratory Distress Syndrome in Coronavirus Disease
Chih-Chao Chiang 1 2 , Michal Korinek 3 4 5 , Wei-Jen Cheng 1 6 7 , Tsong-Long Hwang 3 4 6 8 9
Affiliations
- PMID: 33162887
- PMCID: PMC7583590
- DOI: 10.3389/fphar.2020.572009
Abstract
This review describes targeting neutrophils as a potential therapeutic strategy for acute respiratory distress syndrome (ARDS) associated with coronavirus disease 2019 (COVID-19), a pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Neutrophil counts are significantly elevated in patients with COVID-19 and significantly correlated with disease severity. The neutrophil-to-lymphocyte ratio can serve as a clinical marker for predicting fatal complications related to ARDS in patients with COVID-19. Neutrophil-associated inflammation plays a critical pathogenic role in ARDS. The effector functions of neutrophils, acting as respiratory burst oxidants, granule proteases, and neutrophil extracellular traps, are linked to the pathogenesis of ARDS. Hence, neutrophils can not only be used as pathogenic markers but also as candidate drug targets for COVID-19 associated ARDS.
Keywords: acute respiratory distress syndrome; coronavirus disease 2019; neutrophil extracellular trap; neutrophils; severe acute respiratory syndrome coronavirus 2.